We are live on ! Find out more
ZYNE

Zynerba Pharmaceuticals, Inc
ZYNE

Delisted

ZYNE was delisted on the 10th of October, 2023.

Back to rankings

62 hedge funds and large institutions have $7.97M invested in Zynerba Pharmaceuticals, Inc in 2022 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 13 increasing their positions, 16 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

467% more call options, than puts

Call options by funds: $68K | Put options by funds: $12K

100% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 6

11% more funds holding

Funds holding: 56 → 62 (+6)

19% less repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 16

36% less capital invested

Capital invested by funds: $12.5M → $7.97M (-$4.57M)

Holders
62
Holders Change
+6
Holders Change %
+10.71%
% of All Funds
1.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
12
Increased
13
Reduced
16
Closed
6
Calls
$68K
Puts
$12K
Net Calls
+$56K
Net Calls Change
-$13K

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$424K
2
Millennium Management
Millennium Management
New York
+$334K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$263K
4
Two Sigma Investments
Two Sigma Investments
New York
+$139K
5
Citadel Advisors
Citadel Advisors
Florida
+$136K

Top Sellers

Rank Fund Capital Flow
1
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$615K
2
Mirae Asset Global Investments
Mirae Asset Global Investments
South Korea
-$375K
3
EMG
ETF Managers Group
New Jersey
-$214K
4
PCM
Penserra Capital Management
California
-$155K
5
IEFM
IQ EQ Fund Management
Ireland
-$122K
Name Holding Trade Value Shares
Change 		Change in
Stake
HF
26
HRT Financial
New York
$23K +$37K +32,642 New
TRCT
27
Tower Research Capital (TRC)
New York
$21K +$30.7K +27,034 +1,280%
BWP
28
Bernardo Wealth Planning
Pennsylvania
$20K – – –
UBS Group
29
UBS Group
Switzerland
$20K +$2.26K +1,988 +8%
GSC
30
Ground Swell Capital
South Carolina
$19K +$28.9K +25,445 New
CAN
31
Cetera Advisor Networks
California
$18K -$135 -119 -0.5%
Verition Fund Management
32
Verition Fund Management
Connecticut
$15K -$12K -10,603 -35%
T. Rowe Price Associates
33
T. Rowe Price Associates
Maryland
$14K – – –
KWMG
34
King Wealth Management Group
Florida
$12K – – –
PWA
35
PCG Wealth Advisors
Kansas
$12K +$17.2K +15,200 New
ECM
36
ExodusPoint Capital Management
New York
$11K -$3.83K -3,376 -19%
VF
37
Virtu Financial
New York
$11K +$16.8K +14,812 New
LPL Financial
38
LPL Financial
California
$9K -$501 -442 -3%
Goldman Sachs
39
Goldman Sachs
New York
$8K +$12.9K +11,344 New
AAP
40
Arax Advisory Partners
Colorado
$5K – – –
KFI
41
Key Financial Inc
Pennsylvania
$5K – – –
ETC
42
Exchange Traded Concepts
Oklahoma
$5K +$1.16K +1,018 +17%
Group One Trading
43
Group One Trading
Illinois
$4K -$13K -11,500 -70%
NFSG
44
Newbridge Financial Services Group
Florida
$4K – – –
FCMT
45
Founders Capital Management (Texas)
Texas
$2K – – –
Royal Bank of Canada
46
Royal Bank of Canada
Ontario, Canada
$2K +$2.57K +2,268 New
Rockefeller Capital Management
47
Rockefeller Capital Management
New York
$1K – – –
Toronto Dominion Bank
48
Toronto Dominion Bank
Ontario, Canada
$1K +$741 +653 +162%
HighTower Advisors
49
HighTower Advisors
Illinois
– -$20K -16,650 Closed
TSS
50
Two Sigma Securities
New York
– -$19K -16,367 Closed
1
2
3

ZYNE Hedge Fund Activity: Q3 2022 in Review

62 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Zynerba Pharmaceuticals, Inc (ZYNE) for Q3 2022, worth a combined $7.97M — down 36% from $12.5M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new ZYNE positions and 6 closed out — a net gain of 6 holders — while 13 added to existing stakes and 16 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $424K. The largest seller was D.E. Shaw & Co, cutting an estimated $615K.

  • 62 institutional investors held Zynerba Pharmaceuticals, Inc (ZYNE) as of Q3 2022, up from 56 in Q2 2022.
  • Funds reported $7.97M of Zynerba Pharmaceuticals, Inc stock for Q3 2022, down 36% quarter-over-quarter.
  • 12 funds opened new Zynerba Pharmaceuticals, Inc positions in Q3 2022 and 6 closed out, a net change of +6 holders.
  • The largest Zynerba Pharmaceuticals, Inc buyer in Q3 2022 was Renaissance Technologies, an estimated $424K added.
  • The largest Zynerba Pharmaceuticals, Inc seller in Q3 2022 was D.E. Shaw & Co, an estimated $615K sold.

Based on aggregated 13F filings for Q3 2022.